NASDAQ:PRME Prime Medicine (PRME) Stock Price, News & Analysis $3.14 -0.01 (-0.16%) As of 12:07 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Prime Medicine Stock (NASDAQ:PRME) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Prime Medicine alerts:Sign Up Key Stats Today's Range$3.08▼$3.1750-Day Range$2.81▼$3.7852-Week Range$2.67▼$6.94Volume534,265 shsAverage Volume2.88 million shsMarket Capitalization$568.62 millionP/E RatioN/ADividend YieldN/APrice Target$7.47Consensus RatingModerate Buy Company Overview Prime Medicine, Inc. is a biotechnology company developing genetic medicines using its proprietary Prime Editing platform. The company’s technology is designed to make precise changes to DNA, including the insertion, deletion, or replacement of genetic sequences, with the goal of addressing disease-causing mutations. Prime Medicine is focused on developing treatments for genetic diseases and other serious conditions. Its research programs use Prime Editing in approaches that may modify a patient’s own cells, including ex vivo cell-editing applications in which cells are edited outside the body and then returned to the patient. The company’s development pipeline has included programs for inherited disorders such as chronic granulomatous disease, as well as potential applications in immunology, oncology, and other therapeutic areas. Founded in 2019, Prime Medicine is headquartered in Cambridge, Massachusetts. The company was established around Prime Editing technology developed by researchers including David R. Liu, a professor at Harvard University and the Broad Institute of MIT and Harvard. Prime Medicine’s activities are primarily centered on research, clinical development, and potential commercialization of gene-editing therapies.AI Generated. May Contain Errors. Read More Prime Medicine Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScorePRME MarketRank™: Prime Medicine scored higher than 54% of companies evaluated by MarketBeat, and ranked 449th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingPrime Medicine has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 1 strong buy rating, 7 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialPrime Medicine has a consensus price target of $7.47, representing about 139.4% upside from its current price of $3.12.Amount of Analyst CoveragePrime Medicine has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Prime Medicine's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Prime Medicine are expected to grow in the coming year, from ($0.96) to ($0.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prime Medicine is -2.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prime Medicine is -2.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrime Medicine has a P/B Ratio of 4.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted24.14% of the float of Prime Medicine has been sold short.Short Interest Ratio / Days to CoverPrime Medicine has a short interest ratio ("days to cover") of 13.13, which indicates bearish sentiment.Change versus previous monthShort interest in Prime Medicine has recently increased by 4.97%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPrime Medicine does not currently pay a dividend.Dividend GrowthPrime Medicine does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.36 News SentimentPrime Medicine has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Prime Medicine this week, compared to 3 articles on an average week.Search Interest6 people have searched for PRME on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Prime Medicine to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Prime Medicine insiders have not sold or bought any company stock.Percentage Held by Insiders16.04% of the stock of Prime Medicine is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.37% of the stock of Prime Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Prime Medicine's insider trading history. Receive PRME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prime Medicine and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRME Stock News HeadlinesGene-editing powerhouse and its rivals surge toward a breakoutSeptember 17 at 1:38 PM | msn.comPrime Medicine, Inc. (PRME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16 at 6:32 PM | seekingalpha.comMy next big call (under $1)17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage.September 18 at 1:00 AM | Crypto 101 Media (Ad)Prime Medicine (NASDAQ:PRME) Upgraded at Wall Street ZenSeptember 12, 2026 | americanbankingnews.comPrime Medicine to Participate in Upcoming Investor ConferencesSeptember 3, 2026 | globenewswire.comPrime Medicine: Soon In The ClinicAugust 15, 2026 | seekingalpha.comPrime Medicine: An Initial PrognosisAugust 11, 2026 | seekingalpha.comPrime Medicine Advances First-in-Human Prime Editing Trial in Wilson DiseaseAugust 11, 2026 | tipranks.comSee More Headlines PRME Stock Analysis - Frequently Asked Questions How have PRME shares performed this year? Prime Medicine's stock was trading at $3.47 on January 1st, 2026. Since then, PRME shares have decreased by 10.1% and is now trading at $3.1210. How were Prime Medicine's earnings last quarter? Prime Medicine, Inc. (NASDAQ:PRME) released its earnings results on Thursday, August, 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.24). The business had revenue of $1.15 million for the quarter, compared to analyst estimates of $4.40 million. Prime Medicine had a negative trailing twelve-month return on equity of 188.27% and a negative net margin of 4,613.11%. When did Prime Medicine IPO? Prime Medicine (PRME) raised $175 million in an initial public offering on Thursday, October 20th 2022. The company issued 10,294,118 shares at $16.00-$18.00 per share. Who are Prime Medicine's major shareholders? Prime Medicine's top institutional shareholders include Alphabet Inc. (9.17%), BlackRock Inc. (5.32%), ADAR1 Capital Management LLC (1.10%) and Bank of America Corp DE (0.54%). Insiders that own company stock include David R Liu, Arch Venture Partners Xii, Llc and Robert Nelsen. View institutional ownership trends. How do I buy shares of Prime Medicine? Shares of PRME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Prime Medicine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Prime Medicine investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Intel (INTC), NVIDIA (NVDA), Meta Platforms (META) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/06/2026Today9/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 PRME's financial health is in the Yellow zone, according to TradeSmith. PRME has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PRME Previous SymbolNASDAQ:PRME CIK1894562 Webprimemedicine.com Phone(617) 465-0013FaxN/AEmployees146Year Founded2019Price Target and Rating Average Price Target for Prime Medicine$7.47 High Price Target$11.00 Low Price Target$4.25 Potential Upside/Downside+136.8%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$201.14 million Net Margins-4,613.11% Pretax Margin-4,613.11% Return on Equity-188.27% Return on Assets-59.11% Debt Debt-to-Equity RatioN/A Current Ratio3.05 Quick Ratio3.05 Sales & Book Value Annual Sales$4.07 million Price / Sales140.50 Cash FlowN/A Price / Cash FlowN/A Book Value$0.67 per share Price / Book4.71Miscellaneous Outstanding Shares181,377,000Free Float152,284,000Market Cap$572.24 million OptionableN/A Beta2.34 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:PRME) was last updated on 9/18/2026 by MarketBeat.com Staff. From Our PartnersNVDA CEO says it’s a "once-in-a-generation opportunity"NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...Monument Traders Alliance | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military prote...Banyan Hill Publishing | Sponsored“This is the Perfect Tech Stock”Jeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI compa...Brownstone Research | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRME Stock Alerts